In parallel, the National, Heart, Lung, and Blood Institute has developed a major research initiative, TransOmics for Precision Medicine (TOPMed), that will "couple whole-genome sequencing (WGS) and other -omics data with molecular, behavioral, imaging, environmental, and clinical data from studies focused on heart, lung, blood and sleep disorders" (2). The longterm goal of TOPMed is to uncover factors that "increase or decrease the risk of disease, identify subtypes of disease, and develop more targeted and personalized treatments" (2). Concurrently, the U.S. Food and Drug Administration (FDA) has created the precisionFDA initiative to facilitate the development and standardization of next-generation precision diagnostics and inform advances in regulatory science to benefit individuals and public health. The goal of precisionFDA is to create a "community research and development portal that allows for testing, piloting, and validating existing and new bioinformatics approaches to next generation sequence processing" (3) . With all of the excitement around these big science initiatives and precision health care, it is appropriate to question whether these new programs will accelerate translational research efforts to develop new drugs and devices for patients afflicted with cardiovascular disease. jaccbts@acc.org.
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